Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel product candidates against validated molecular targets for indications with high unmet medical need in the United States. Its lead candidate, AT-007, has completed Phase 3 for galactosemia in healthy volunteers and adults, and is in pediatric clinical study for galactosemia in children, for treating the enzyme sorbitol dehydrogenase, and for phosphomannomutase enzyme-CDG. The company also develops AT-001 in Phase 3 for diabetic cardiomyopathy and diabetic peripheral neuropathy, and AT-003 in preclinical studies for diabetic retinopathy. It has an exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Incorporated in 2016 and headquartered in New York, New York, Applied Therapeutics operates as a subsidiary of Cycle Group Holdings Limited as of February 3, 2026.